These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B. Clin Cancer Res; 2009 Nov 01; 15(21):6582-94. PubMed ID: 19861448 [Abstract] [Full Text] [Related]
35. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Kerl K, Prins C, Saurat JH, French LE. Br J Dermatol; 2006 Dec 01; 155(6):1197-200. PubMed ID: 17107389 [Abstract] [Full Text] [Related]
39. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Mineo JF, Scheffer A, Karkoutly C, Nouvel L, Kerdraon O, Trauet J, Bordron A, Dessaint JP, Labalette M, Berthou C, Labalette P. Invest Ophthalmol Vis Sci; 2008 Nov 01; 49(11):4738-45. PubMed ID: 18552383 [Abstract] [Full Text] [Related]